STERIS (NYSE:STE) Releases Earnings Results

STERIS (NYSE:STE) issued its quarterly earnings results on Wednesday. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02, Briefing.com reports. The company had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.03 earnings per share. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Stock Performance

Shares of STE stock traded up $3.69 during mid-day trading on Friday, reaching $219.19. The stock had a trading volume of 1,071,783 shares, compared to its average volume of 638,994. STERIS has a 1-year low of $195.47 and a 1-year high of $248.24. The company has a current ratio of 2.41, a quick ratio of 1.49 and a debt-to-equity ratio of 0.33. The firm has a market cap of $21.62 billion, a price-to-earnings ratio of 50.04 and a beta of 0.85. The business’s fifty day moving average is $232.29 and its 200-day moving average is $227.97.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s dividend payout ratio is presently 52.05%.

Analyst Ratings Changes

A number of analysts recently commented on STE shares. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday. JMP Securities reiterated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Wednesday, August 7th. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. KeyCorp increased their price target on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Finally, Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and increased their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $253.00.

Insider Transactions at STERIS

In other news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.14% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.